James Lovgren

CEO & Co-Founder @AspiroTx | #Biotech Innovator | #LifeScience Exec | Revolutionizing treatment for #COPD & #Asthma | World Traveler | @Giants Fan

[James Lovgren @JamesLovgren]

Looking forward to participating in #RESISanDiego and connecting with investors & strategic partners.

@AspiroTx is developing an inhaled peptidomimetic therapy that mimics the protective power of CC16.

Attending #RESISanDiego, let’s connect.

#biotech #COPD #ASthama @LSciNation

[James Lovgren @JamesLovgren]

On #WorldAsthmaDay, we recognize the need to go beyond symptom control. Patients need therapies that address the disease, not just flare ups.

@AspiroTx We are working toward restoring lung function & preventing disease progression.

#AsthmaAwareness #RespiratoryHealth #Biotech

[James Lovgren @JamesLovgren]

Heading to @atscommunity Respiratory Innovation Summit next month in Orlando.

We will be presenting new data showing a key step forward for our program, with a stable aerosol formulation enabling consistent delivery to the lung.

#ATS2026 #RIS2026 #Biotech

[James Lovgren @JamesLovgren]

Excited to attend Investival Showcase March 10–11

@AspiroTx is developing an inhaled, disease-modifying therapy for asthma and COPD by mimicking the protective biology of CC16.

Meeting with investors to discuss early-stage therapeutic development.

#InvestivalUSA #Biotech

[James Lovgren @JamesLovgren]

Joining ABD Capital Connect at #JPMWeek2026 to share Aspiro’s progress in respiratory innovation. In SF? Let’s connect.
@AspiroTx #copd #asthma #Biotech

[Aspiro Therapeutics @AspiroTx]

Today we recognize the millions living with COPD, a leading cause of morbidity & mortality.

Up to 70% of adults with COPD remain undiagnosed

We’re developing a therapy to reduce inflammation, strengthen epithelial defenses, and modify disease progression💙

#WorldCOPDDay #COPD

[Aspiro Therapeutics @AspiroTx]

🌍 World Lung Day 🌍
We stand with patients, caregivers, & all working toward healthier breathing for all. 💙

Aspiro Therapeutics is developing an inhaled CC16 therapy to reduce inflammation, strengthen defenses, and change the course of disease.

#WorldLungDay #COPD #Asthma

[Aspiro Therapeutics @AspiroTx]

Early COPD is getting long overdue attention. This CNN piece highlights how lung damage can begin decades before diagnosis.

At Aspiro, we are developing an inhaled CC16-based therapy targeting these early pathways. @katiahetter @CNN

🔗 https://t.co/8UQRH6qNmf

[James Lovgren @JamesLovgren]

Excited to join #RESIBoston next month for 3 days of hybrid partnering across biotech and diagnostics.

I’ll be in Boston all week for Biotech Week (Sept 16–19). Let’s connect if you’re focused on respiratory innovation or early-stage biotech.
https://t.co/2moSD6IG5K

[Aspiro Therapeutics @AspiroTx]

We’re proud to share that Dr. Stefano Guerra and @Dr_Ledford Ledford, two of our co-founders, are contributing to NIH-funded research on CC16 and early COPD. Dr. Guerra leads the $3.8M NIAID study with Dr. Ledford as co-investigator. #COPD #NIH #Biotech
https://t.co/DVIENEUQYO

[James Lovgren @JamesLovgren]

@Nicole_Paulk

[James Lovgren @JamesLovgren]

@Nicole_Paulk Maybe we'll cross paths at Biotech Week in Boston.

[James Lovgren @JamesLovgren]

GSK’s $12B COPD deal highlights the value of first in class respiratory innovation. At @AspiroTx , we are developing a CC16 inspired inhaled therapy to modify disease in asthma and COPD, not just manage symptoms.
https://t.co/d1NE8hkAV5
#biotech #COPD #asthma #respiratoryhealth

[Aspiro Therapeutics @AspiroTx]

We’re excited to welcome @MattBritz and Dr. Anne Dixon as advisors to Aspiro! Matt brings deep biotech leadership, and Anne is a leading pulmonary expert. Their guidance will support our CC16-based approach for asthma and COPD.
🔗 https://t.co/Dwstrlv0Yf
#biotech #asthma #COPD

[Aspiro Therapeutics @AspiroTx]

Excited to share that Aspiro Therapeutics has been selected to present at the #BIO2025 Startup Stadium in Boston!

@JamesLovgren will present our inhaled therapy inspired by CC16,

Join us Thurs, June 19. Let’s connect.

#StartupStadium #Biotech #COPD #Asthma #RespiratoryHealth

[Aspiro Therapeutics @AspiroTx]

We’re just days away! Aspiro CEO @JamesLovgren will present at #RIS2025 this Saturday, May 17 at 2:00 PM PT.

Join us as we share our CC16-driven approach to transforming care for COPD & asthma. 🌬️

🔗 Agenda: https://t.co/lwZfxQMC0p
#COPD #Asthma #Biotech #ATS2025

[Aspiro Therapeutics @AspiroTx]

On #WorldAsthmaDay, we stand with millions living with asthma—and the urgent need for better care.

At Aspiro, we’re developing a therapy inspired by the body’s own defenses to restore lung function and prevent progression.

#asthma #CC16 #biotechforgood #WorldAsthmaDay2025

[James Lovgren @JamesLovgren]

Looking forward to presenting Aspiro’s innovative, CC16-driven science at the 2025 Respiratory Innovation Summit next month!

[Aspiro Therapeutics @AspiroTx]

Excited to share that Aspiro CEO @JamesLovgren will present at #RIS2025 on Saturday, May 17 at 2:00 PM PT in San Francisco! We’re honored to be a Showcase Company advancing new solutions in #respiratoryhealth. 🌬️

Agenda: https://t.co/lwZfxQMC0p
#ATS2025 #COPD #Asthma #Biotech

[Aspiro Therapeutics @AspiroTx]

Excited to share that Aspiro CEO @JamesLovgren will present at #RIS2025 on Saturday, May 17 at 2:00 PM PT in San Francisco! We’re honored to be a Showcase Company advancing new solutions in #respiratoryhealth. 🌬️

Agenda: https://t.co/lwZfxQMC0p
#ATS2025 #COPD #Asthma #Biotech

[Bruce Booth @LifeSciVC]

Biotech Venture Creation: The Benefits Of Scarcity.

The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies.

https://t.co/iDN3NSLCT5